Antibody-drug conjugates (ADCs), also known as "biological missiles", are targeted medicines that deliver chemotherapeutics to cancer cells. Until now, 13 received FDA approval and over 100 are being investigated at the clinical stages. Creative Biolabs is professionalized in antibody-associated drug discovery and has versatile in vivo platforms for ADC development including xenograft and syngeneic tumor models.
The reasonable selection of targets is crucial for ADCs development. Below we summarized a list of human cancer cell lines for xenograft models that would be used to validate common ADC targets.
ADC Targets
BCMA CD19 CD22 CD30 CD33CD79bCEACAMc-MetEGFREp-CAMFolate receptor alphaHER2HER3LIV1MesothelinNectin-4PSMAROR1Tissue FactorTrop-2
|
Tumor Types
|
Cell Lines
|
|
Myeloma
|
KMS-28BM, KMS-11, NCI-H929, MM.1S, MOLP-8
|
|
Tumor Types
|
Cell Lines
|
|
Leukemia
|
Nalm6
|
|
Lymphoma
|
Daudi, DoHH2, Mino, Raji, REC-1, SU-DHL-8
|
|
Tumor Types
|
Cell Lines
|
|
Leukemia
|
Nalm6
|
|
Lymphoma
|
Ramos, Raji
|
|
Lung Cancer
|
A549, H1650, H1975
|
|
Tumor Types
|
Cell Lines
|
|
Lymphoma
|
HDLM-2, L-540
|
|
Tumor Types
|
Cell Lines
|
|
Leukemia
|
HEL 92.1.7, MV 4-11, HL-60, Kasumi-1, THP-1, SET-2, PL-21
|
|
Tumor Types
|
Cell Lines
|
|
Lymphoma
|
Daudi, DoHH2, Namalwa, Pfeiffer, Raji, SU-DHL-8
|
|
Myeloma
|
MOLP-8, NCI-H929
|
|
Tumor Types
|
Cell Lines
|
|
Colorectal
|
HT55, LS180, NCI-H684, SW48, SK-CO-1, T84
|
|
Gastric
|
MKN45, NUGC4, SNU-5, SNU-620
|
|
Pancreatic
|
ASPC-1, BxPC-3
|
|
Tumor Types
|
Cell Lines
|
|
Gastric
|
Hs 746.T, MKN45, SNU-5
|
|
Renal
|
A-498, ACHN, Caki-1, 786-O
|
|
Tumor Types
|
Cell Lines
|
|
Head & Neck
|
Cal 27, FaDu, SCC-9
|
|
Esophageal
|
OE21
|
|
Skin
|
A431
|
|
Tumor Types
|
Cell Lines
|
|
Colorectal
|
Caco-2, COLO201, HT-55, Lovo, LS180, SW480, T84
|
|
Breast
|
CAL-51, HCC1937, MCF-7, MDA-MB-361, MDA-MB-468
|
|
Tumor Types
|
Cell Lines
|
|
Cervical
|
HeLa
|
|
Ovarian
|
OVSAHO
|
|
Tumor Types
|
Cell Lines
|
|
Breast
|
BT-474, HCC1954, MDA-MB-361
|
|
Lung
|
NCI-H2170
|
|
Ovarian
|
SK-OV-3
|
|
Tumor Types
|
Cell Lines
|
|
Breast
|
BT-474, BT-483, HCC1428, MCF-7, MDA-MB-361, T-47D, ZR-75-1
|
|
Colorectal
|
COLO 201, HT 29, HT 55, LS180, LS411N, SW620
|
|
Gastric
|
NUGC-4
|
|
Liver
|
Hep 3B, Hep G2, Huh-7, JHH
|
|
Melanoma
|
A375, COLO 829, SK-MEL-24, SK-MEL-28, SK-MEL-5
|
|
Tumor Types
|
Cell Lines
|
|
Breast
|
HCC1500, HCC2218, KPL-1, MCF-7, ZR-75-1
|
|
Myeloma
|
KMS-11, KMS-28BM, MM1.S, MOLP-8, NCI-H929, RPMI8226
|
|
Neuroblastoma
|
SK-N-AS, SH-SY5Y
|
|
Prostate
|
DU145, LNCap, VCaP
|
|
Tumor Types
|
Cell Lines
|
|
Ovarian
|
OVCAR-3, SK-OV-3
|
|
Pancreas
|
AsPC-1, BxPC-3
|
|
Gastric
|
NUGC4
|
|
Tumor Types
|
Cell Lines
|
|
Bladder
|
HT1376, RT-112
|
|
Breast
|
BT-474, BT-483, HCC1599, MDA-MB-175, T47D, ZR-75-1
|
|
Esophageal
|
T.Tn, TE-9
|
|
Head and Neck
|
BICR16, Cal-27, FaDu, SCC-9
|
|
Tumor Types
|
Cell Lines
|
|
Prostate
|
LNCap, VCap
|
|
Tumor Types
|
Cell Lines
|
|
Breast
|
MDA-MB-231, MDA-MB-468
|
|
Lung
|
A-549, Calu-1, Calu-3, NCI-H226, NCI-H2882, NCI-H358
|
|
Ovarian
|
MCAS, OV7, TOV-21G
|
|
Tumor Types
|
Cell Lines
|
|
Bladder
|
J82, ScaBER, T24
|
|
Head and Neck
|
CAL-27, SCC-9, SCC-25
|
|
Pancreatic
|
AsPC-1, BxPC-3, Panc 02.13
|
|
Tumor Types
|
Cell Lines
|
|
Bladder
|
RT-112, UM-UC-1
|
|
Breast
|
HCC1937, HCC1500, MCF10A, MCF-7, T47D, ZR-75-1
|
|
Head and Neck
|
FaDu, SCC-9
|
|
Pancreatic
|
BxPC-3, CAPAN-2, KP-2, Panc 02.13
|
Our Capabilities that Support ADCs Research
Animal models
Fig. 1 Mechanism of action for ADC drugs (Cheng-Sanchez et al. 2022).
-
Xenograft mouse models
-
Established tumor bank of cell line-derived xenografts (CDXs) for accurate selection of targets.
-
Patient-derived xenografts (PDXs) for modeling metastases and tumor heterogenicity.
-
Models customizable with human immune system reconstitution and human immune checkpoint-knockin mice.
-
Syngeneic mouse models
-
Murine tumor cell lines engineered to express human tumor targets.
a. Modified cell lines include CT26, 4T1 and B16F10.
b. Human targets include BCMA, CCR4, CD19, CD38, CD47, CEA, CEACAM1, CLDN18.2, CXCR2, CXCR4, EPCAM, HER2, PD-L1, PD-L2, ROR1, TNFR2.
-
Localized and disseminated tumor models available for multiple tumor cell lines.
Preclinical evaluation
-
Dose finding studies and dose fractionation studies.
-
Anti-tumor activity: survival, tumor burden, body weight, histology.
-
Correlation analysis of relative tumor growth vs intratumoral payload/catabolite exposure.
You may also be interested in:
CAR-T And CAR-NK Efficacy Evaluation in Mouse Models
Oncolytic Virus Efficacy Evaluation in Mouse Models
Cancer Vaccine Efficacy Evaluation in Mouse Models
Creative Biolabs supports customized solutions that will quickly establish and advance your projects. Contact us to discuss your project in detail today.
Reference
-
Cheng-Sánchez, I. et al., Antibody-Drug Conjugates Containing Payloads from Marine Origin. Mar. Drugs 2022, 20, 494.
For Research Use Only.
Copyright © 2024 Creative Biolabs.
